Caplin Point continues to be a consistent performer with Q4 results.
Summary of q4 concall:
Caplin Point Laboratories reported a 15.5% YoY revenue growth and a 22.4% YoY increase in profit after tax. Contribution margins improved by approximately 3%
Caplin Steriles achieved over 50% revenue growth in the US-focused regulated market business, contributing 75% of product revenue.
Challenges in attracting the right talent have led to some delays in completing API projects. The company is also exploring direct sales to hospitals and clinics in the US market and actively seeking acquisition opportunities.
Subscribe To Our Free Newsletter |